Invitrogen plans to launch a new drug-screening platform early in the second quarter as a key part of its strategy to build its nascent screening-services business, company officials told BioCommerce Week.

The SelectScreen Profiling and Screening Services platform was initially launched in 2004 and builds off of the firm's kinase-screening business. The new platform — enabled by SSi Robotics' automation technology — will enable Invitrogen researchers to perform assays more quickly at higher throughput, the officials said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.